Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential

Liu, Pinyan; Mao, Yongcui; Xie, Ye; Wei, Jiayun; Yao, Jia

doi:10.1186/s13287-022-03041-5

Cited by 44 publications

(34 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the promising results of therapeutic candidates for ALD in preclinical studies, their efficacy has been less than expected or not observed in clinical trials. The therapeutic effects of stem cells have been proved in chronic liver diseases such as ALD, NAFLD and acute liver failure [176,177]. Pluripotent stem cells, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can differentiate into hepatocyte-like cells [178].…”

Section: Stem Cell Therapy For Aldmentioning

confidence: 99%

Section: Limitations Of Stem Cells Including Mscs Therapymentioning

confidence: 99%

“…Because numerous pre-clinical studies have proved the prospective potential of stem cell therapy, an increasing number of clinical trials are being conducted [177,225]. However, actual clinical application of stem cells for chronic liver disease is still challenging [22,177,225]. In order to use stem cells in therapies, exhaustive control for their quality is essential, but characteristics of MSCs are heterogeneous, depending on the health status, genetics, sex, and age of the donor [198,225].…”

Section: Limitations Of Stem Cells Including Mscs Therapymentioning

confidence: 99%

See 2 more Smart Citations

Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease

Han

Lee

Hur

et al. 2022

Cells

View full text Add to dashboard Cite

Alcoholic liver disease (ALD) is a globally prevalent chronic liver disease caused by chronic or binge consumption of alcohol. The therapeutic efficiency of current therapies for ALD is limited, and there is no FDA-approved therapy for ALD at present. Various strategies targeting pathogenic events in the progression of ALD are being investigated in preclinical and clinical trials. Recently, mesenchymal stem cells (MSCs) have emerged as a promising candidate for ALD treatment and have been tested in several clinical trials. MSC-released factors have captured attention, as they have the same therapeutic function as MSCs. Herein, we focus on current therapeutic options, recently proposed strategies, and their limitations in ALD treatment. Also, we review the therapeutic effects of MSCs and those of MSC-related secretory factors on ALD. Although accumulating evidence suggests the therapeutic potential of MSCs and related factors in ALD, the mechanisms underlying their actions in ALD have not been well studied. Further investigations of the detailed mechanisms underlying the therapeutic role of MSCs in ALD are required to expand MSC therapies to clinical applications. This review provides information on current or possible treatments for ALD and contributes to our understanding of the development of effective and safe treatments for ALD.

show abstract

Section: Stem Cell Therapy For Aldmentioning

confidence: 99%

Section: Limitations Of Stem Cells Including Mscs Therapymentioning

confidence: 99%

Section: Limitations Of Stem Cells Including Mscs Therapymentioning

confidence: 99%

See 1 more Smart Citation

Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease

Han

Lee

Hur

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…It is important to note that the percentage of stem cells among umbilical cord mononuclear cells decrease as the pregnancy progresses, from 11% at week 17 to 1% at week 38; however, these cells have a distinct advantage over bone marrow HSCs because they graft 10 to 50 times better on hosts xenogenesis (10).…”

Section: Introductionmentioning

confidence: 99%

Molecular Process of Stem Cells in Modern Biology

Shahid¹,

Rehman²,

Hyder³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Stem cells have a wide range of traits, including the ability to self-renewal and differential interactions between various cell types that vary with their location within tissue and their immediate surroundings. Inhibitors of both are influenced by the cell cycle, genes involved in chromosomal rearrangements, critical developmental proteins, and signaling pathways. Wnt, Notch, Hedgehog Pathways, BMI-1, OCT3/4, ARF, NANOG, p16Ink4a, and this includes HOXB4, SOX2, and their homologous paralog, govern self-renewal. Stem cells and their molecular pathways that regulate self-renewal and differentiation hold great promise for theoretical and practical studies. Keyword: gene regulation of stem cell self-renewal and differentiation genes for BMI-1, NANOG, OCT3, OCT4, p16Ink4a, SOX2, microenvironment, ARF protein proteins 1 (hedgehog), proteins 2 (Wnt.), and receptors 3 (notch).

show abstract

“…Stem cell transplantation has emerged as the most promising treatment for liver fibrosis since the advent of regenerative medicine (7)(8)(9). Stem cells are a population of cells with self-renewal, proliferation, and pluripotent differentiation potential that can differentiate into multiple cell types under defined conditions (10,11).…”

mentioning

confidence: 99%

Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis

et al. 2023

View full text Add to dashboard Cite

Liver fibrosis is a fibrogenic and inflammatory process that results from hepatocyte injury and is characterized by hepatic architectural distortion and resultant loss of liver function. There is no effective treatment for advanced fibrosis other than liver transplantation, but it is limited by expensive costs, immune rejection, and postoperative complications. With the development of regenerative medicine in recent years, mesenchymal stem cell (MSCs) transplantation has become the most promising treatment for liver fibrosis. The underlying mechanisms of MSC anti-fibrotic effects include hepatocyte differentiation, paracrine, and immunomodulation, with immunomodulation playing a central role. This review discusses the immune cells involved in liver fibrosis, the immunomodulatory properties of MSCs, and the immunomodulation mechanisms of MSC-based strategies to attenuate liver fibrosis. Meanwhile, we discuss the current challenges and future directions as well.

show abstract

Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential

Cited by 44 publications

References 148 publications

Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease

Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease

Molecular Process of Stem Cells in Modern Biology

Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis

Contact Info

Product

Resources

About